Cost effectiveness analysis of six non insulin agents for type 2 diabetes in Iran using a patient level simulation with UKPDS OM2
Abstract
Type 2 diabetes mellitus (T2DM) is a global healthcare challenge, requiring cost-effective treatments to improve patient outcomes and resource use. This study assesses the cost-effectiveness of six non-insulin agents (NIAs)-pioglitazone, metformin, dapagliflozin, sitagliptin, empagliflozin, and liraglutide for T2DM management in Iran. Using the UKPDS Outcomes Model 2 (UKPDS-OM2), a 40-year simulation from the healthcare system perspective analyzed data from 440 Iranian patients in the Diabetes Care (DiaCare) study, evaluating direct medical costs and quality-adjusted life years (QALYs). Costs were locally sourced, while treatment effects and complication disutility values came from international evidence. Incremental cost-effectiveness ratios (ICERs) were compared to a threshold of one-time GDP per capita, with uncertainty evaluated via 100 bootstrap iterations. Subgroup analyses were conducted based on sex, age (< 55 vs. ≥55 years), and diabetes duration (< 10 vs. ≥10 years), using the same simulation framework and assumptions. Pioglitazone proved least costly at $1,376.20 PPP with 8.47 QALYs, dominating sitagliptin and empagliflozin, and outperforming metformin, dapagliflozin, and liraglutide, which showed higher costs and limited QALY gains. Subgroup analyses showed that pioglitazone was cost-effective in men, younger patients, and those with longer diabetes duration, while metformin was preferred in women, older patients, and those with shorter disease duration.…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.